

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

Attachment 6
August 25, 2026

- 【Therapeutic category】 429 Other antitumor agents
- 【Non-proprietary name】 Atezolizumab (genetical recombination)
Avelumab (genetical recombination)
Durvalumab (genetical recombination)
Tremelimumab (genetical recombination)
- 【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
8. IMPORTANT PRECAUTIONS N/A	8. IMPORTANT PRECAUTIONS <u>Uveitis may occur. Whether ocular abnormalities occur should be examined periodically. In addition, patients should be instructed to immediately seek medical attention if any ocular abnormalities are observed.</u>
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions N/A	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Uveitis</u>

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.